Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00531)
Name
Pimavanserin
Synonyms    Click to Show/Hide the Synonyms of This API
Pimavanserin; 706779-91-1; 1-(4-Fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea; ACP-103; UNII-JZ963P0DIK; Pimavanserin free base; JZ963P0DIK; 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea; 706779-91-1 (free base); N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide; Pimavanserin [INN]; 706782-28-7; Pimanavserin; methyltrimethylacetate; AC-5273; Pimavanserin(ACP-103); SCHEMBL675165; Nuplazid (proposed trade name); GTPL8423; CHEMBL2111101; C25H34FN3O2; DTXSID90990906; CHEBI:133017; BDBM139370; HMS3742A03; BCP11618; EBD38047; MFCD09953792; ZINC16159083; AKOS015902593; CS-3378; DB05316; ME-0240; SB16963; NCGC00390656-01; NCGC00390656-02; HY-14557; FT-0653701; A14434; 779P911; A836958; J-503297; Q7194603; 1-[(4-fluorophenyl)methyl]-1-(1-methyl-4-piperidinyl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea; N-[(4-Fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}carbamimidic acid; N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea
Clinical Status
Approved
Disease Indication Parkinsonism ICD-11: 8A00 [1]
PubChem CID
10071196
Formula
C25H34FN3O2
Canonical SMILES
CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C
InChI
1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)
InChIKey
RKEWSXXUOLRFBX-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=10071196"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 427.6 Topological Polar Surface Area 44.8
XlogP 4.5 Complexity 523
Heavy Atom Count 31 Rotatable Bond Count 8
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 4
Full List of Drug Formulations (DFMs) Containing This API
          Pimavanserin 17 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Saccharin sodium anhydrous; Magnesium stearate; Talc; Titanium dioxide; Polyethylene glycol 3350; Hypromellose 2910 (15 mpa.s); Microcrystalline cellulose; Starch, corn
                   Dosage Form Oral Tablet
                   Company ACADIA Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Saccharin sodium anhydrous DIG Info Carbonic anhydrase I (Ki = 18540 nM) [2]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Polyethylene glycol 3350 DIG Info Albendazole monooxygenase (Protein expression upregulation) [3]
          Pimavanserin Tartrate 10 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium Stearate; Pregelatinized Starch; Silicified Microcrystalline Cellulose; Polyethylene Glycol; Polyvinyl Alcohol; Red Iron Oxide; Talc; Titanium Dioxide; Yellow Iron Oxide
                   Dosage Form Tablet
                   Company Acadia Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Polyvinyl alcohol DIG Info Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) [4]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Polyethylene glycol 4000 DIG Info Albendazole monooxygenase (Inhibition ratio < 40 %) [5]
Pregelatinized starch DIG Info Multidrug resistance protein 1 (Protein expression downregulation) [3]
          Pimavanserin Tartrate 34 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium Stearate; Microcrystalline Cellulose; Black Iron Oxide; Fd&C Blue 1; Hypromellose; Titanium Dioxide; Yellow Iron Oxide
                   Dosage Form Capsule
                   Company Acadia Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 1 DIG Info Solute carrier SLCO2B1 (Ki = 13 uM) [6]
Hypromellose DIG Info Cytochrome P450 3A5 (IC50 = 19.4 uM) [4]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
References
1 FDA label for approved pimavanserin from the official website of the U.S. Food and Drug Administration.
2 Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15; 17(14):5054-8.
3 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.
4 Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.
5 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
6 Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16009-16018.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.